# Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

> **NCT00835328** · PHASE1,PHASE2 · TERMINATED · sponsor: **Diva De Leon** · enrollment: 14 (actual)

## Conditions studied

- Congenital Hyperinsulinism

## Interventions

- **DRUG:** Exendin (9-39)
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT00835328
- **Lead sponsor:** Diva De Leon
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08-26
- **Primary completion:** 2017-01-28
- **Final completion:** 2017-01-28
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Study stopped prematurely to test a new formulation of Exendin (9-39)
- **Last updated:** 2020-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00835328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00835328, "Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00835328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*